每经头条（nbdtoutiao）——对话马斯克脑机接口"一号受试者"：大脑植入芯片23个月，我正重新夺回 人生的独立 （记者 王晓波） 截至发稿，奥比中光市值为347亿元。 每经AI快讯，奥比中光（SH 688322，收盘价：86.5元）12月26日晚间发布公告称，公司限售股份约 2643.61万股将于2026年1月7日解禁并上市流通，占公司总股本比例为6.59%。 2024年1至12月份，奥比中光的营业收入构成为：AIoT占比52.82%，生物识别占比40.93%，工业三维测 量占比4.69%，其他占比0.92%，其他业务占比0.64%。 ...

每经AI快讯，奥比中光（SH 688322，收盘价：82元）12月11日晚间发布公告称，公司第二届第二十二 次董事会会议于2025年12月11日在公司会议室以现场结合通讯表决方式召开。会议审议了《关于修订 < 公司章程> 的议案》等文件。 2024年1至12月份，奥比中光的营业收入构成为：AIoT占比52.82%，生物识别占比40.93%，工业三维测 量占比4.69%，其他占比0.92%，其他业务占比0.64%。 （记者 曾健辉） 截至发稿，奥比中光市值为329亿元。 每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 ...

Core Viewpoint - The passing of independent director Xie Zhiming is acknowledged by Lens Technology, which expresses condolences and gratitude for his contributions to the company [4][6]. Group 1: Company Announcement - Lens Technology announced the unfortunate passing of independent director Xie Zhiming due to illness, and the board expressed deep condolences and sympathy to his family [4]. - Following Xie Zhiming's death, the board's membership decreased from 7 to 6, remaining above the legal minimum but below the number stipulated in the company's articles of association [6]. - The company plans to promptly appoint a new independent director in accordance with relevant regulations and will ensure that the current independent directors temporarily fulfill the responsibilities until a new appointment is made [6]. Group 2: Company Operations and Financials - Lens Technology's main business includes the production and assembly of components such as glass, sapphire, ceramics, metals, plastics, touch modules, biometric systems, and acoustic products [6]. - The company has initiated a "de-Apple" strategy to reduce dependency on Apple, exploring new business opportunities, including humanoid robots, which have garnered significant interest from institutional investors [6][7]. - For the first three quarters of 2025, Lens Technology reported revenue of 53.663 billion yuan, a year-on-year increase of 16.08%, and a net profit of 2.843 billion yuan, up 19.91% [7].

Core Viewpoint - The recent passing of independent director Xie Zhiming has led to a reduction in the board members of Lens Technology, although the company assures that its operations will not be adversely affected [1][3]. Company Overview - Lens Technology specializes in the production, assembly, and support of various components including glass, sapphire, ceramics, metals, plastics, touch modules, biometric systems, and acoustic products [4]. - The company was listed on the Shenzhen Stock Exchange in 2015 and has applied for a listing on the Hong Kong Stock Exchange as of March 31, 2025 [4]. Recent Developments - Lens Technology is undergoing a "de-Apple" process to reduce its dependency on Apple, exploring new business opportunities [4]. - In early November, the company engaged with 226 institutional investors, focusing on its humanoid robot business, which is expected to generate significant revenue [4]. - The company anticipates shipping thousands of humanoid robots and over ten thousand quadruped robotic dogs this year, with preliminary revenue estimates from the robotics business reaching several hundred million yuan [4]. Financial Performance - For the first three quarters of 2025, Lens Technology reported a revenue of 53.663 billion yuan, a year-on-year increase of 16.08%, and a net profit attributable to shareholders of 2.843 billion yuan, up 19.91% [4]. - The basic earnings per share stood at 0.57 yuan, with the stock price closing at 28.66 yuan per share and a total market capitalization of 151.4 billion yuan as of December 1 [4].

Core Points - The independent director of Lens Technology, Xie Zhiming, passed away due to illness, leading to a reduction in the board members from 7 to 6, below the required number as per the company's articles of association [1] - The company will promptly follow procedures to appoint a new independent director and fulfill information disclosure obligations [1] - Current independent directors will temporarily assume Xie Zhiming's responsibilities until a new director is elected [1] Company Overview - Lens Technology specializes in the production, assembly, and support of various structural and functional components, including glass, sapphire, ceramics, metals, plastics, touch modules, biometric systems, and acoustic components [2] - The company was listed on the Shenzhen Stock Exchange in 2015 and has applied for a main board listing on the Hong Kong Stock Exchange as of March 31, 2025 [2] - As one of the "three giants" in the Apple supply chain, the company is actively diversifying its business to reduce reliance on Apple, with new business areas being developed [2] Financial Performance - In the first three quarters of the year, Lens Technology achieved a revenue of 53.663 billion yuan, representing a year-on-year growth of 16% [2] - The net profit attributable to shareholders was 2.843 billion yuan, reflecting a year-on-year increase of 20% [2] - As of December 1, the company's stock price was 28.66 yuan per share, with a market capitalization of 149.7 billion yuan [3]

Core Points - The company is undergoing a change in its board of directors, with the current number of board members reduced from 7 to 6, prompting the need for a new independent director [2][3] - The company is actively diversifying its business to reduce reliance on Apple, with a focus on humanoid robots and other new business ventures [3] Group 1: Company Overview - The company, Lens Technology, specializes in the production and assembly of various components including glass, sapphire, ceramics, metals, plastics, touch modules, biometric, and acoustic products [3] - Lens Technology was listed on the Shenzhen Stock Exchange in 2015 and has applied for a listing on the Hong Kong Stock Exchange as of March 31, 2025 [3] Group 2: Financial Performance - In the first three quarters of the year, the company achieved a revenue of 53.663 billion yuan, representing a year-on-year growth of 16% [3] - The net profit attributable to shareholders for the same period was 2.843 billion yuan, showing a year-on-year increase of 20% [3] Group 3: Business Development - The company has initiated a "de-Apple" strategy to lessen its dependency on Apple, with significant exploration into new business areas [3] - In early November, the company engaged with 226 institutional investors, focusing on the expected output and revenue from its humanoid robot business, projecting thousands of units sold this year [3] - The company anticipates revenue from its robotics business to be in the range of several hundred million yuan, positioning itself as a leading manufacturer in the embodied intelligent hardware sector [3]

Company Overview - Aobi Zhongguang (SH 688322) announced the convening of its 2025 second board meeting on November 28, 2023, to discuss the proposal for the reappointment of the accounting firm for the 2025 fiscal year [1] - The current market capitalization of Aobi Zhongguang is 33.1 billion yuan [1] Revenue Composition - For the fiscal year 2024, Aobi Zhongguang's revenue composition is as follows: - AIoT accounts for 52.82% - Biometric recognition accounts for 40.93% - Industrial 3D measurement accounts for 4.69% - Other businesses account for 0.92% - Additional other business accounts for 0.64% [1]

Group 1 - The core point of the article is that Aobo Zhongguang (SH 688322) held its 20th meeting of the second board of directors on October 24, 2025, to discuss the conditions for the second vesting period of the 2022 restricted stock incentive plan [1] - For the year 2024, Aobo Zhongguang's revenue composition is as follows: AIoT accounts for 52.82%, biometric recognition accounts for 40.93%, industrial 3D measurement accounts for 4.69%, and other businesses account for 1.56% [1] - As of the time of reporting, Aobo Zhongguang has a market capitalization of 34.4 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion US dollars this year, indicating a hot secondary market for biomedicine [1] - There is a discussion on why fundraising in the primary market is facing challenges despite the active secondary market, as highlighted by the conversation with Lu Gang, a partner at Chuangdong Investment [1]

Group 1 - The company, Aobo Zhongguang, announced a share buyback of approximately 120,000 shares, representing 0.03% of its total share capital, with a total expenditure of about 10.01 million RMB [1][1][1] - The share buyback occurred at a price range of 82 to 86.5 RMB per share [1][1][1] - As of the report, Aobo Zhongguang's market capitalization stands at 32.4 billion RMB [1][1][1] Group 2 - For the fiscal year 2024, Aobo Zhongguang's revenue composition is as follows: AIoT accounts for 52.82%, biometric recognition for 40.93%, industrial 3D measurement for 4.69%, and other businesses for 1.56% [1][1][1]

Group 1 - The core point of the article is that Aibijungguang (SH 688322) announced a board meeting to discuss a share repurchase plan and provided a breakdown of its revenue composition for 2024 [1][1][1] Group 2 - The company will hold its 19th board meeting on October 13, 2025, to review the share repurchase proposal [1] - For the year 2024, the revenue composition is as follows: AIoT 52.82%, biometric recognition 40.93%, industrial 3D measurement 4.69%, other businesses 0.92%, and miscellaneous 0.64% [1][1][1] - As of the report, the market capitalization of Aibijungguang is 33.1 billion yuan [1]